Why doesn't phase 3 of PP405 start straight away? Chat 12/19/2025
Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity July 1st - Early H2 - Breezula
Discussion on hair loss treatments, focusing on Breezula, with mentions of Minoxidil, finasteride, RU58841, Pyrilutamide, GT20029, and PP405. Breezula's effectiveness is uncertain, with some trials showing minimal regrowth.
community PP405: Regrows Hair In 8 Weeks. Is This The Miracle Cure?
PP405 is considered as a potential hair regrowth treatment, but users are skeptical due to past product failures. They compare it to Minoxidil and Finasteride, questioning its effectiveness and the intentions of pharmaceutical companies.
community Can anyone give me a quick 2026 update of the most promising new hair loss drugs to come?
New hair loss treatments like Breezula and a version of Minoxidil for hair regrowth are in advanced trials and may be available in a few years. Clascoterone and other treatments like oral and topical Minoxidil, Finasteride, and Dutasteride are also discussed, with some users experiencing side effects from Finasteride.
community My summation of PP405 - looks promising
PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.
community PP405 Phase 2a press release with early results
PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.
Related Research
6 / 6 results
research Recent Advances in Drug Development for Hair Loss
This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.
research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
research ПОРІВНЯЛЬНИЙ АНАЛІЗ МЕТОДІВ ВІДНОВЛЕННЯ ВОЛОССЯ В УКРАЇНІ ТА США
This research provides a comprehensive comparison of hair restoration methods used in Ukraine and the USA, examining the effectiveness of surgical and non-surgical treatments for alopecia, including FUE and FUT hair transplantation, PRP therapy, and low-level laser therapy.
research Use of Vitamins and Minerals in the Treatment of Hair Loss: A Cross-Sectional Survey among Dermatologists in Saudi Arabia
This study found that a majority of dermatologists in Saudi Arabia believe in using vitamins and minerals to treat hair loss but emphasized the need for more research to confirm their effectiveness.
research Oestrogen functions in skin and skin appendages
This review discusses the influence of oestrogens on various skin components and highlights their modulatory roles and receptor pathways, but it reports no new clinical results.
research Beyond Minoxidil: Off-Label Therapies for Male Androgenetic Alopecia—A Systematic Review with Network Meta-Analyses
In this network meta-analysis, the researchers reported that topical minoxidil 5% was the most effective off-label therapy for increasing hair density in men with androgenetic alopecia, while other treatments like melatonin and cetirizine showed potential benefits, highlighting a need for further comparative trials.